ArticleFrontiers in oncology2025
Case Report: Rare meets rare-miliary prostate cancer brain metastasis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Miliary brain metastasis (MM), consisting of innumerable miliary lesions in perivascular location, is a rare disease entity with an estimated incidence of 3.8% among patients with brain metastasis (BM). Similarly, with an approximated incidence of less than 2%, prostate cancer (PC)-related BM is also an infrequent presentation; however, it is more common in patients with neuroendocrine differentiation. To the best of our knowledge, only one other case of MM secondary to PC has been reported. This case report discusses two additional cases of PC-related MM, a condition otherwise predominantly observed secondary to pulmonary adenocarcinoma. Case presentations: The first case describes a patient in his 60s known for metastatic PC with suspected neuroendocrine differentiation and presenting with musculoskeletal pain, lethargy, and status epilepticus. Contrast-enhanced computer tomography (CT) angiogram and magnetic resonance imaging (MRI) of the head and neck revealed diffuse and innumerable foci in the cerebral hemispheres, brainstem, and cerebellum. The second case discusses a similarly aged male patient with biopsy-proven Conclusion: Given its rarity, notably in patients with PC, there are no specific and established diagnostic criteria for MM, a condition with ominous prognosis seemingly related to neuroendocrine differentiation in men with PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.